上海医药拟挂牌转让中美施贵宝30%股权

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) plans to transfer its 30% stake in the subsidiary China Medical Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (referred to as "China Medical Bristol-Myers Squibb") through a public listing at a minimum price of 1.023 billion yuan [1] Group 1 - The company will no longer hold any equity in China Medical Bristol-Myers Squibb after the transaction is completed [1] - This transaction is not expected to have a significant impact on the company's normal operations and financial status [1] - The move is aimed at protecting state-owned asset rights and maximizing asset value, aligning with the interests of the company and all shareholders [1]